Botswana Medicines Regulatory Authority (BoMRA) is the National Regulatory Authority established in terms of the Medicines and Related Substances Act (2013) to provide for the, regulation of medicines, medical devices, cosmetics and other related substances in the public interest.
Grand-Pa products, both powder and tablets, were suspended from registration in June 2021. The suspension followed the temporary supply halt initiated by the Market Authorization Holder, (MAH) GlaxoSmithKline CH South Africa, affecting Botswana and other markets.
The Botswana Medicines Regulatory Authority (BoMRA) wishes to announce the reinstatement of Grand-Pa Headache Powder with new packaging for use in Botswana.
The newly reinstated Grand-Pa Headache Powder product now comes in a revamped packaging system, stick packs made of Glazed Imitation Parchment (GIP) paper with a polythene layer. Registered pack sizes include 5, 12, 25, and 38 stick packs.
Importation is strictly limited to products packed in the new Stick packs. The public is urged to always remain vigilant to ensure they buy or use the appropriate products.
Any person found in possession of the previously registered Grandpa Products, not fitting the above mentioned pack sizes and packaging, will be subject to prosecution under Section 23 of the Medicines and Related Substances Act (MRSA). This section prohibits the importation, distribution, sale, storage, and advertising of unregistered medical products. Offenders may face a fine of up to P100,000.00 and/or imprisonment for a maximum period of 10 years.